ArticleMaterials today. Bio2026
Engineered microalgal extracellular vesicles for efficient doxorubicin delivery and improved therapeutic efficacy in breast cancer.
Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Breaking barriers in peritoneal fibrosis: extracellular vesicles as promising diagnostic and therapeutic strategy.Annals of medicine · 2026Review
- Scalable and Controlled Production of Microalgae-derived Extracellular Vesicles Using a Differential Tangential Flow Filtration Protocol.Journal of extracellular biology · 2026Article
- Aerosolized microalgal derived extracellular vesicles reduce oxidative stress and inflammation in bronchial epithelial macrophage cocultures at the air liquid interface.Discover nano · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Extracellular vesicles (EVs) have emerged as versatile and biocompatible nanocarriers for drug delivery, offering significant advantages over synthetic nanoparticles, which often suffer from rapid clearance, immunogenicity, and limited clinical translation. In this study, we introduce nanoalgosomes, a new class of EVs derived from the marine microalga
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.